Inflammatory breast cancer: Unique biological and therapeutic considerations

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages e568-e576

  Woodward, Wendy A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; CD133 ANTIGEN; HERMES ANTIGEN; UVOMORULIN;

BODY MASS; BREAST FEEDING; CANCER RESISTANCE; DISEASE FREE SURVIVAL; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH VESSEL METASTASIS; MACROPHAGE ACTIVATION; MASTECTOMY; MESENCHYMAL STEM CELL; PARENCHYMA; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; RADIATION FIELD; REVIEW; SKIN EDEMA; SKIN MANIFESTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR RECURRENCE; GENETICS; INFLAMMATORY BREAST NEOPLASMS; PATHOLOGY;

HUMANS; INFLAMMATORY BREAST NEOPLASMS;

EID: 84960344389     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00146-1     Document Type: Review

References (62)

1. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008, 35:41-50.
2. Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005, 11:7637-7642.
3. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004, 10:7965-7971.
4. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 2002, 21:3631-3643.
5. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003, 88:718-725.
6. Kleer CG, van Golen KL, Braun T, Merajver SD Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001, 14:458-464.
7. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ E-cadherin's dark side: possible role in tumor progression. Biochim Biophys Acta 2012, 1826:23-31.
8. Woodward WA Postmastectomy radiation therapy for inflammatory breast cancer: is more better?. Int J Radiation Oncol 2014, 89:1004-1005.
9. Friedl P, Hegerfeldt Y, Tusch M Collective cell migration in morphogenesis and cancer. Int J Dev Biol 2004, 48:441-449.
10. Kardash E, Reichman-Fried M, Maitre JL, et al. A role for Rho GTPases and cell-cell adhesion in single-cell motility in vivo. Nat Cell Biol 2010, 12:47-53.
11. Mahooti S, Porter K, Alpaugh ML, et al. Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion. Oncotarget 2010, 1:131-147.
12. Comen E, Norton L, Massague J Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 2011, 8:369-377.
13. Norton L Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005, 10:370-381.
14. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008, 109:417-426.
15. Iwamoto T, Bianchini G, Qi Y, et al. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 2011, 125:785-795.
16. Masuda H, Baggerly KA, Wang Y, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 2013, 15:R112.
17. Van Laere SJ, Ueno NT, Finetti P, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res 2013, 19:4685-4696.
18. Woodward WA, Krishnamurthy S, Yamauchi H, et al. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat 2013, 138:761-772.
19. Masuda H, Brewer TM, Liu DD, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 2014, 25:384-391.
20. Bertucci F, Finetti P, Vermeulen P, et al. Genomic profiling of inflammatory breast cancer: a review. Breast 2014, 23:538-545.
21. Bekhouche I, Finetti P, Adelaide J, et al. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS One 2011, 6:e16950.
22. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8558-8565.
23. Nguyen DM, Sam K, Tsimelzon A, et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006, 12:5047-5054.
24. Robertson FM, Petricoin EF, Van Laere SJ, et al. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus 2013, 2:497.
25. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010, 60:351-375.
26. Polyak K Pregnancy and breast cancer: the other side of the coin. Cancer Cell 2006, 9:151-153.
27. Schedin P Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006, 6:281-291.
28. Le MG, Arriagada R, Bahi J, et al. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?. Breast 2006, 15:355-362.
29. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010, 116:4933-4943.
30. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011, 4:1021-1219.
31. Sun X, Casbas-Hernandez P, Bigelow C, et al. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat 2012, 131:1003-1012.
32. O'Brien J, Lyons T, Monks J, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol 2010, 176:1241-1255.
33. Stein T, Salomonis N, Nuyten DS, van de Vijver MJ, Gusterson BA A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J Mammary Gland Biol Neoplasia 2009, 14:99-116.
34. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res 2004, 6:R92-109.
35. Bambhroliya A Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple negative breast cancer. MS thesis 2015, University of Texas.
36. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
37. Huh SJ, Clement K, Jee D, et al. Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells. Stem Cell Reports 2015, 4:297-311.
38. Choudhury S, Almendro V, Merino VF, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell 2013, 13:117-130.
39. Atkinson RL, Yang WT, Rosen DG, et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 2013, 15:R77.
40. Rios AC, Fu NY, Lindeman GJ, Visvader JE In situ identification of bipotent stem cells in the mammary gland. Nature 2014, 506:322-327.
41. Lyons TR, O'Brien J, Borges VF, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 2011, 17:1109-1115.
42. Lacerda L, Debeb BG, Smith D, et al. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res 2015, 17:42.
43. Hill DA, Preston-Martin S, Ross RK, Bernstein L Medical radiation, family history of cancer, and benign breast disease in relation to breast cancer risk in young women, USA. Cancer Causes Control 2002, 13:711-718.
44. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002, 158:220-235.
45. Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992, 326:781-785.
46. Doody MM, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study. Spine 2000, 25:2052-2063.
47. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008, 100:1368-1379.
48. Haricharan S, Dong J, Hein S, et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. eLife 2013, 2:e00996.
49. Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol 2014, 32:2018-2024.
50. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001, 92:1775-1782.
51. Hoffman HJ, Khan A, Ajmera KM, Zolfaghari L, Schenfeld JR, Levine PH Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases. Am J Clin Oncol 2014, 37:315-321.
52. Rehman S, Reddy CA, Tendulkar RD Modern outcomes of inflammatory breast cancer. Int J Radiation Oncol 2012, 84:619-624.
53. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007, 9:201-209.
54. Lerebours F, Vacher S, Andrieu C, et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41.
55. Monneur A, Bertucci F, Viens P, Goncalves A Systemic treatments of inflammatory breast cancer: an overview. Bull Cancer 2014, 101:1080-1088.
56. Scotti V, Desideri I, Meattini I, et al. Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach. Cancer Treat Rev 2013, 39:119-124.
57. Coates PJ, Appleyard MV, Murray K, et al. Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model. Cancer Res 2010, 70:9808-9815.
58. Woodward W, Koay E, Takiar V Radiation therapy for inflammatory breast cancer: technical considerations and diverse clinical scenarios. Breast Cancer Manage 2014, 3:43-52. 57.
59. Takiar V, Akay CL, Stauder MC, et al. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus 2014, 3:166.
60. Salama JK, Chmura SJ The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol 2014, 41:790-797.
61. Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection may improve survival and local disease control in stage IV inflammatory breast cancer. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 1102.
62. Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 2014, 120:1319-1328.